ENDOMETRIAL CANCER

This study tested whether taking the hormone-blocking drug letrozole for two years after standard surgery and treatment could help prevent endometrial (uterine) cancer from returning. It compared letrozole against just watching and waiting (observation) in patients with a specifi…

This early-stage study tested a new oral medication called ATX-559 in patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the drug behaves in the body. The trial was terminated after enrolling…

This early-stage study aimed to test the safety and find the right dose of a new drug called BLU-222 for people with advanced solid tumors that have stopped responding to standard treatments. It involved about 50 patients with cancers like breast, ovarian, and gastric cancer. The…

This early-stage study tested a new radioactive drug designed to target and destroy advanced solid tumors. It involved 78 patients with various cancers who had run out of standard treatment options. The main goals were to check the treatment's safety, find the right dose, and see…

This early-stage study tested a personalized cancer treatment that modifies a patient's own immune cells to recognize and attack their specific tumor mutations. The trial enrolled 8 adults with advanced solid tumors (including ovarian, lung, pancreatic, and colorectal cancers) wh…

This early-phase study tested a new drug called PRO1107 in patients with advanced solid tumors that had stopped responding to other treatments. The main goals were to find a safe dose and see if the drug could shrink tumors in cancers like ovarian, lung, breast, and others. The s…

This study tested whether the drug niraparib could help control advanced solid tumors in patients whose cancer has a specific genetic change called a PALB2 mutation. It involved 22 adults with various cancers (like breast, lung, or pancreatic) that had spread or were locally adva…

This early-stage study tested a new oral drug called NKT3447 in adults with advanced solid tumors that had progressed despite standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study was later terminated and focused on specif…

This first-in-human study tested a new cancer drug called PHN-010 in patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, determine the right dose, and see if it could shrink tumors. The trial incl…

This study tested whether combining two existing drugs, copanlisib and fulvestrant, could help control advanced endometrial or ovarian cancers that are hormone-sensitive and have specific genetic changes. The trial aimed to find a safe dose and see if the combination could shrink…

This study tested whether combining two existing cancer drugs (lenvatinib and pembrolizumab) could help control recurrent endometrial cancer specifically in Black patients. The trial was designed to address a lack of data in this population but was terminated early after enrollin…